Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Psychopharmacol Bull ; 51(4): 122-127, 2021 11 03.
Article in English | MEDLINE | ID: mdl-34887604

ABSTRACT

Clozapine is a second generation antipsychotic agent which is drug of choice for treatment resistant schizophrenia. Tachycardia and postural hypotension are most frequently observed cardiovascular adverse effects, but reports on new-onset persistently elevated blood pressure are sparse. Mechanisms underlying clozapine induced hypertension also remain unclear. We report the case of a 32 year old normotensive male with persistently elevated systolic and diastolic blood pressure after clozapine initiation. Hypertension persisted throughout the phase of dose optimization and dose stabilization at 300 mg/day, requiring an addition of a beta blocker (atenolol) after a month of observation. The 24 hour urinary catecholamines were within normal limits. Autonomic function tests revealed severe loss of parasympathetic activity and cardiac autonomic tone. The case adds to limited information on autonomic dysfunction as a potential factor in clozapine induced hypertension.


Subject(s)
Antipsychotic Agents , Clozapine , Hypertension , Adult , Antipsychotic Agents/adverse effects , Blood Pressure , Clozapine/adverse effects , Humans , Hypertension/chemically induced , Male , Schizophrenia, Treatment-Resistant/drug therapy
3.
Clin Neuropharmacol ; 42(2): 64-65, 2019.
Article in English | MEDLINE | ID: mdl-30747749

ABSTRACT

OBJECTIVE: Long-acting depot preparations of antipsychotics are the mainstay of treatment for patients with schizophrenia who show nonadherence to their medications. Olanzapine pamoate is one of the recently approved long-acting depot psychotropic preparations that have shown its efficacy both in clinical trials and in clinical uses against the illness. However, emerging literature indicates toward a cluster of adverse effects known as postinjection delirium/sedation syndrome (PDSS). METHODS: We here present a case of PDSS in a woman with paranoid schizophrenia. After maintaining well for almost 1½ years, she developed PDSS at her 31st scheduled long-acting olanzapine injection. RESULTS: Several features of PDSS including its mechanism and course have been discussed. CONCLUSIONS: More research is necessary to understand the syndrome and the association between PDSS and long-acting olanzapine injection. Clinicians should keep in mind that PDSS may worsen compliance in an index patient and affect the course of the illness.


Subject(s)
Antipsychotic Agents/adverse effects , Delirium/chemically induced , Hypnotics and Sedatives/adverse effects , Olanzapine/adverse effects , Schizophrenia, Paranoid/drug therapy , Adult , Antipsychotic Agents/administration & dosage , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/adverse effects , Delirium/diagnosis , Delirium/psychology , Drug-Related Side Effects and Adverse Reactions/diagnosis , Drug-Related Side Effects and Adverse Reactions/psychology , Female , Humans , Hypnotics and Sedatives/administration & dosage , Olanzapine/administration & dosage , Schizophrenia, Paranoid/diagnosis , Schizophrenia, Paranoid/psychology , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL
...